The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention

Yi-Chia Lee, Tony Hsiu-Hsi Chen, Han-Mo Chiu, Chia-Tung Shun, Hung Chiang, Tzeng-Ying Liu, Ming-Shiang Wu, Jaw-Town Lin, Yi-Chia Lee, Tony Hsiu-Hsi Chen, Han-Mo Chiu, Chia-Tung Shun, Hung Chiang, Tzeng-Ying Liu, Ming-Shiang Wu, Jaw-Town Lin

Abstract

Objective: To evaluate the benefit of mass eradication of Helicobacter pylori infection in reducing premalignant gastric lesions.

Design: Mass eradication of H pylori infection was started from 2004 for a Taiwanese population with prevalent H pylori infection, who were >30 years of age. Participants positive for the (13)C-urea breath test underwent endoscopic screening and 1-week clarithromycin-based triple therapy. For subjects whose initial treatment failed, 10-day levofloxacin-based triple therapy was administered. The main outcome measures were changes in the prevalence of H pylori infection and premalignant gastric lesions, and changes in the incidence of premalignant gastric lesions and gastric cancer before (1995-2003) and after (2004-2008) chemoprevention using various comparators.

Results: The reduction in H pylori infection was 78.7% (95% CI 76.8% to 80.7%), and the estimated incidence of re-infection/recrudescence was 1% (95% CI 0.6% to 1.4%) per person-year. The effectiveness of reducing the incidence of gastric atrophy resulting from chemoprevention was significant at 77.2% (95% CI 72.3% to 81.2%), while the reduction in intestinal metaplasia was not significant. Compared with the 5-year period before chemoprevention and in the absence of endoscopic screening, the effectiveness in reducing gastric cancer incidence during the chemoprevention period was 25% (rate ratio 0.753, 95% CI 0.372 to 1.524). The reduction in peptic ulcer disease was 67.4% (95% CI 52.2% to 77.8%), while the incidence of oesophagitis was 6% (95% CI 5.1% to 6.9%) after treatment.

Conclusions: Population-based eradication of H pylori infection has led to a significant reduction in gastric atrophy at the expense of increased oesophagitis. The ultimate benefit in reducing gastric cancer incidence and its mortality should be validated by a further long-term follow-up.

Trial registration: ClinicalTrials.gov NCT00155389.

Conflict of interest statement

Competing interests: None.

Figures

Figure 1
Figure 1
Gastric cancer prevention programmes implemented on Matsu Island, in chronological order. EGD, oesophagogastroduodenoscopy; UBT, urea breath test.
Figure 2
Figure 2
Individual factors associated with the occurrence of intestinal metaplasia after chemoprevention. The multivariate model adjusted for all variables is shown in the forest plot. HDL-C, high-density lipoprotein cholesterol.
Figure 3
Figure 3
Incidence of gastric cancer between 1995 and 2008, correlated with mass eradication of Helicobacter pylori infection. The trend in gastric cancer incidence over time is represented by the solid line for subjects on Matsu Island and by the dotted line for residents of Taiwan. The closed arrow indicates the start of the chemoprevention programme in 2004, involving endoscopic screening and H pylori treatment.
Figure 4
Figure 4
Individual factors associated with the occurrence of endoscopic oesophagitis after chemoprevention. The multivariate model adjusted for all variables is shown in the forest plot. HDL-C, high-density lipoprotein cholesterol.

References

    1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–40
    1. Fox JG, Wang TC. Inflammation, atrophy and gastric cancer. J Clin Invest 2007;117:60–9
    1. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974–83
    1. Mera R, Fontham ET, Bravo LE, et al. Long term follow-up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536–40
    1. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244–9
    1. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–9
    1. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187–94
    1. Saito D, Boku N, Fujioka T, et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. [Abstract]. Gastroenterology 2005;128:A4
    1. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392–7
    1. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012;75:39–46
    1. Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;16:875–85
    1. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121–8 Erratum in: Ann Intern Med 2009;151:516.
    1. Liu TY, Wu CY, Lin JT, et al. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen 2006;13(Suppl 1):S2–5
    1. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. Helicobacter 2006;11:418–24
    1. Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004;100:1734–43
    1. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–81
    1. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova International classification. Am J Surg Path 2000;24:167–76
    1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–81
    1. Quasi-experiments: interrupted time-series designs. In: Cook TD, Campbell DT, eds. Quasi-Experimentation: Design & Analysis Issues for Field Settings. Boston: Houghton Mifflin Co, 1979:207–32
    1. Cancer Statistics Taiwan Cancer Registry. (accessed 20 Feb 2011).
    1. Parsonnet J, Harris RA, Hack HM, et al. Modeling the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150–4
    1. Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142–8
    1. Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559–68
    1. Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a Markov model. World J Gastroenterol 2008;14:3021–7
    1. Yeh JM, Kuntz KM, Ezzati M, et al. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2009;124:157–66
    1. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–9
    1. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and non-steroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914–23
    1. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010;59:572–8
    1. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507–14
    1. Mazzoleni LE, Francesconi CF, Sander GB. Mass eradication of Helicobacter pylori: feasible and advisable? Lancet 2011;378:462–4
    1. de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104:1342–5
    1. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588–90
    1. Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008;198:553–60
    1. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut 2009;58:174–81

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj